GLMD Galmed Pharmaceuticals Ltd

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of May 2020

001-36345

(Commission File Number)

GALMED PHARMACEUTICALS LTD.

(Exact name of Registrant as specified in its charter)

16 Tiomkin St.

Tel Aviv 6578317, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x      Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

On May 17, 2020, Dr. Tali Gorfine notified Galmed Pharmaceuticals Ltd. (the “Company”) that due to personal reasons she would need to reduce the scope of her activities, starting July 2020. This decision is not related to operations of the Company. The Company initiated a search for a new Chief Medical Officer who would be based in the United States, with a view to expanding the Company’s presence in the United States. Dr. Gorfine intends to support the transition period as required and continue to support the Company’s clinical activities.

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form S-8 (Registration No. 333-206292 and 333-227441) and the Company’s Registration Statement on Form F-3 (Registration No. 333-223923).

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Mar 2024 to Apr 2024

Galmed Pharmaceuticals (NASDAQ:GLMD)
Historical Stock Chart
From Apr 2023 to Apr 2024